TUMOUR REVIEWSystematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer☆
References (80)
- et al.
Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months
Eur J Cancer
(1993) - et al.
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer [see comments,Lancet 1990;335: 853–854, 1033]
Lancet
(1990) - et al.
Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer [letter]
Eur J Cancer
(1995) - et al.
Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study
J Steroid Biochem
(1985) - et al.
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen
J Steroid Biochem
(1985) - et al.
Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer
Eur J Cancer
(1994) - et al.
Chemotherapy with or without high-dose medroxyprogesterone acetate in ooestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group
Eur J Cancer
(1992) - et al.
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer
J Steroid Biochem Mol Biol
(1992) - et al.
High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer
Eur J Cancer Clin Oncol
(1987) - et al.
Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients
Ann Oncol
(1991)
Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer [see comments: Ann Oncol 1993;4: 712–13]
Ann Oncol
(1993)
Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study
Ann Oncol
(1994)
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer
Eur J Cancer
(1995)
The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial
Eur J Cancer
(1993)
Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? [see comments: Ann Oncol 1993;4: 712–13]
Ann Oncol
(1993)
A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast
Eur J Cancer
(1997)
Chemotherapy for metastatic breast cancer – when is enough enough?
Eur J Cancer
(1997)
Does blinding of readers affect the results of meta-analyses? [letter]
Lancet
(1997)
Scientific misconduct in a breast-cancer chemotherapy trial: response of University of the Witwatersrand
Lancet
(2000)
Lancet
(1992)
Confronting publication bias: a cohort design for meta-analysis
Stat Med
(1987)
A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer
New Engl J Med
(1985)
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis
Am J Clin Oncol
(1982)
Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women
Am J Clin Oncol
(1982)
Treatment of metastatic breast cancer in oestrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF
Cancer
(1982)
J Clin Oncol
(1986)
Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system
Surg Today
(1995)
Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study of Cancer and Leukemia Group B
Cancer
(1979)
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
New Engl J Med
(1987)
A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma
Br J Cancer
(1987)
Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial
J Clin Oncol
(1993)
A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer [see comments: J Clin Oncol 1989; 7: 403–4]
J Clin Oncol
(1988)
J Clin Oncol
(1991)
A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma
Cancer
(1992)
Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial
Sem Oncol
(1994)
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study
J Clin Oncol
(1987)
Cited by (169)
Abducens nerve palsy due to clivus metastasis in a patient with breast carcinoma: A rare case
2024, International Journal of Surgery Case ReportsPhase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines
2023, European Journal of CancerDesign, cytotoxic effects on breast cancer cell line (MDA-MB 231), and molecular docking of some maleimide-benzenesulfonamide derivatives
2021, Journal of the Indian Chemical SocietyCell repopulation, rewiring metabolism, and immune regulation in cancer radiotherapy
2020, Radiation Medicine and ProtectionCitation Excerpt :Cancer stem cells (CSCs, also termed as stem-like cancer cells or tumor-initiating cells) were originally identified in myeloid leukemia5,6 and then many other human cancers.7–13 CSCs are well-defined in tumor resistance, including their resistant phenotype observed in RT and chemotherapy.14,15 The CSC concept, illustrated as a hierarchical embryonic organization, is now further supported by increasing clinical and experimental results.
- ☆
Funded by the Australian National Health and Medical Research Council National Breast Cancer Centre.
Copyright © 2000 Published by Elsevier Ltd. All rights reserved.